QURE uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy uniQure Eligible to Receive More Than $2 Billion, Including $450 Million in Upfront Cash, $1.6 Billion https://www.globenewswire.com/news-release/2020/06/24/2052987/0/en/uniQure-Announces-License-Agreement-with-CSL-Behring-to-Commercialize-Hemophilia-B-Gene-Therapy.html